Purpose: This study explored the clinical characteristics, diagnosis and treatments of primary blepharospasm. Methods: In this retrospective analysis, 100 patients with blepharospasm were enrolled. Data were collected from medical records and face-to-face interviews with patients and their families. Results: The age of onset was 56.4 ± 2.7 (range, 32-76 years). The duration between onset and accurate diagnosis was 38.7 ± 36.0 months (range, 2-120 months). Dry eyes occurred in 54% of the patients. The initial diagnostic accuracy was 10%. Dry eye syndrome, conjunctivitis/keratitis and myasthenia gravis caused the most confusion in the differential diagnosis. Regular botulinum toxin type A injections improved both eyelid spasms and subjective ocular symptoms in all patients. Conclusions: Regular botulinum toxin type A injections improved both eyelid spasms and subjective ocular symptoms in blepharospasm patients. The differentiation of primary blepharospasm differentiation from dry eye syndrome, conjunctivitis/keratitis and myasthenia gravis must be improved.

Keywords:
Focal dystonia, Blepharospasm, Dry eyes, Photophobia, Myasthenia gravis, Botulinum toxin
1.
Hallett M, Evinger C, Jankovic J, Stacy M: Update on blepharospasm: report from the BEBRF international workshop. Neurology 2008;71:1275-1282.
2.
Hwang WJ, Tsai CF: Motor vehicle accidents and injuries in patients with idiopathic blepharospasm. J Neurol Sci 2014;339:217-219.
3.
Hwang WJ: Demographic and clinical features of patients with blepharospasm in southern Taiwan: a university hospital-based study. Acta Neurol Taiwan 2012;21:108-114.
4.
Biuk D, Karin AA, Matić S, Barać J, Benasić T, Stiglmayer N: Quality of life in patients with blepharospasm. Coll Antropol 2013;37:29-33.
5.
Elston JS, Marsden CD, Grandas F, Quinn NP: The significance of ophthalmological symptoms in idiopathic blepharospasm. Eye (Lond) 1988;2:435-439.
6.
Grandas F, Elston J, Quinn N, Marsden CD: Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry 1988;51:767-772.
7.
Defazio G, Livrea P: Epidemiology of primary blepharospasm. Mov Disord 2002;17:7-12.
8.
Peckham EL, Lopez G, Shamim EA, Richardson SP, Sanku S, Malkani R, et al: Clinical features of patients with blepharospasm: a report of 240 cases. Eur J Neurol 2011;18:382-386.
9.
Defazio G, Martino D, Aniello MS, Masi G, Abbruzzese G, Lamberti S, Valente EM, Brancati F, Livrea P, Berardelli A: A family study on primary blepharospasm. J Neurol Neurosurg Psychiatry 2006;77:252-254.
10.
Kazuo T, Tsutomu F: Dry eye and Meige's syndrome. Br J Ophthalmol 1997;81:439-442.
11.
Lu R, Huang R, Li K, Zhang X, Yang H, Quan Y, Li Q: The influence of benign essential blepharospasm on dry eye disease and ocular inflammation. Am J Ophthalmol 2014;157:591-597.e1-e2.
12.
Davide M, Giovanni D, Giovanni A, et al: Relationship between eye symptoms and blepharospasm: a multicenter case-control study. Mov Disord 2005;20:1564-1570.
13.
Defazio G, Abbruzzese G, Aniello MS, Di Fede R, Esposito M, Fabbrini G, et al: Eye symptoms in relatives of patients with primary adult-onset dystonia. Mov Disord 2012;27:305-307.
14.
Martino D, Liuzzi D, Macerollo A, Aniello MS, Livrea P, Defazio G: The phenomenology of the geste antagoniste in primary blepharospasm and cervical dystonia. Mov Disord 2010;25:407-412.
15.
Loyola DP, Camargos S, Maiaand D, Cardoso F: Sensory tricks in focal dystonia and hemifacial spasm. Eur J Neurol 2013;20:704-707.
16.
Hara K, Matsuda A, Kitsukawa Y, Tanaka K, Nishizawa M, Tagawa A: Botulinum toxin treatment for blepharospasm associated with myasthenia gravis. Mov Disord 2007;22:1363-1364.
17.
Fabbrini G, Berardelli I, Moretti G, Pasquini M, Bloise M, Colosimo C: Psychiatric disorders in adult-onset focal dystonia: a case-control study. Mov Disord 2010;25:459-465.
18.
Drake DD, Erik CB: Additional clinical observations on psychiatric disorders in adult-onset focal dystonia: a case control study. Mov Disord 2011;26:1572; author reply 1573.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.